Jim Simons Nurix Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 246,400 shares of NRIX stock, worth $5.58 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

246,400

Previous 324,000 23.95%

Holding current value

$5.58 Million

Previous $6.76 Million 18.19%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$18.93 - $25.69 $1.47 Million - $1.99 Million	-77,600 Reduced 23.95%	246,400 $5.53 Million
Q2 2024 Aug 09, 2024	BUY	$12.02 - $21.3 $1.74 Million - $3.08 Million	144,700 Added 80.7%	324,000 $6.76 Million
Q1 2024 May 13, 2024	BUY	$7.77 - $15.66 $498,057 - $1 Million	64,100 Added 55.64%	179,300 $2.64 Million
Q4 2023 Feb 13, 2024	BUY	$4.25 - $10.71 $375,700 - $946,764	88,400 Added 329.85%	115,200 $1.19 Million
Q3 2023 Nov 14, 2023	BUY	$7.86 - $10.08 $210,648 - $270,144	26,800 New	26,800 $211,000
Q1 2023 May 12, 2023	SELL	$8.56 - $13.26 $768,688 - $1.19 Million	-89,800 Reduced 75.65%	28,900 $257,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $14.59 $447,644 - $662,386	45,400 Added 61.94%	118,700 $1.3 Million
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $556,083 - $893,431	-45,100 Reduced 38.09%	73,300 $955,000
Q2 2022 Aug 12, 2022	BUY	$7.88 - $14.82 $332,536 - $625,404	42,200 Added 55.38%	118,400 $1.5 Million
Q1 2022 May 13, 2022	BUY	$12.94 - $29.65 $986,028 - $2.26 Million	76,200 New	76,200 $1.07 Million

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.07B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account